Top Markets
#1 Islamic Coin Islamic Coin +151.54%
#2 Akedo Akedo +66.39%
#3 Glidr Glidr +51.75%
#4 DOVU DOVU +48.78%
#5 Velvet Velvet +41.51%
#6 Cross Cross +35.02%
#7 Black Phoenix Black Phoenix +34.13%
#8 Cap Cap +20.45%
#9 DoubleZero DoubleZero +15.18%
#10 GRVT Token GRVT Token +9.99%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Vaxil Bio Ltd. Vaxil Bio Ltd.

Vaxil Bio Ltd.

VXL
Rank in Stocks #39492
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing... Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
Share Price
$0.1174299
Last synced: 2026-08-13
Market Cap
$467.84K
Change (1 day)
-8.57%
Change (1 year)
1.38%
Country
CA
Trade Vaxil Bio Ltd. (VXL)

Category

Healthcare
Revenue for Vaxil Bio Ltd. (VXL)
Revenue in Aug 2026 TTM: 0
According to Vaxil Bio Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Vaxil Bio Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE